Weblogic Authors: Yeshim Deniz, Elizabeth White, Michael Meiner, Michael Bushong, Avi Rosenthal

News Feed Item

BIOLASE's CEO Responds to Claims Made by Oracle Partners L.P.

IRVINE, CA -- (Marketwired) -- 05/16/14 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase®, and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that Federico Pignatelli, the Company's Chairman and Chief Executive Officer, has responded to claims and allegations made by Oracle Partners L.P. ("Oracle") in a press release dated May 14, 2014.

Federico Pignatelli, Chairman and CEO, said, "I would prefer not to respond to Oracle's absurd claims but their press release dated May 14, 2014 is an inappropriate attempt to mislead our stakeholders and accordingly it must be addressed. As such, I would like to bring the following items to the attention of our stakeholders:

  • Oracle has been blatantly trying to gain control of BIOLASE's Board of Directors (our "Board") since September 2013. This is evidenced in a large number of documents BIOLASE has obtained in discovery during our recent litigation against Oracle. It is now apparent to me that Oracle conspired to have Mr. Paul Clark and Mr. Jeffrey Nugent appointed to our Board, all the while purporting that they were uninterested parties. Together with Dr. Fred Moll, who was seemingly working while a BIOLASE's Board Member with Oracle, this very group attempted to illegally gain control of our Board. I believe that once they had control of our Board, their plan was to push through a financing that would be highly dilutive to our other shareholders. Oracle has proposed such a financing to our Board last August and it has been rejected. This type of dilutive financing could essentially pass control of BIOLASE to Oracle without requiring them to put forth a tender offer to our shareholders that would typically result in a premium to market.
  • I believe that the primary goal of the lawsuit filed by Oracle against BIOLASE on March 8th 2014 was to block the public offering under our universal shelf registration statement contemplated by the Board which would dilute Oracle's ownership position.
  • The director dispute arose because Messrs. Clark and Nugent did not properly disclose that they were conspiring with Oracle to gain control of our Board.
  • I believe that Oracle's lawsuit had a dramatic and meaningful impact on our end of quarter sales for the three months ended March 31, 2014. Like most companies that sell capital equipment, a significant portion of our sales closes in the last month of a quarter, and the uncertainty that the lawsuit created regarding the composition of our Board most definitely impacted the decision making process of most of buyers.
  • Despite its representations, Oracle has no experience whatsoever with dental equipment companies and, to the best of my knowledge, has not invested in the dental field prior to their investment in BIOLASE. Oracle's proposed director candidates of Messrs. Clark, Nugent, and Varma and Dr. Moll have had no experience in the dental business or even, with the exception of Dr. Moll, in medical equipment. In fact, their primary experience is in cosmetics, pharmaceuticals, and finance.
  • On several occasions, Oracle's representatives have told me that they actually disliked the dental business because they don't understand it and that they believe we should divest of our long standing dental business in order to concentrate our efforts in the application of our proprietary WaterLase technology in various other medical fields, which Oracle believes present vast opportunities for return on their investment.
  • I trust that the pending decision by the Chancery Court of Delaware will shed light on the true nature of Oracle's attempted takeover of BIOLASE. It is my firm belief that Oracle's lawsuit was an effort to disguise their ultimate goal to gain control of BIOLASE without paying the substantial premium that our stockholders deserve.
  • Oracle itself is a small fund with barely $700 million under management and that has vastly under performed in recent months, while tracking below its piers and Biotech indexes. Oracle is mostly invested in Biotech money losing and illiquid microcaps in which they own large stakes, in several of them along side long time partner Jack Schuler of Crabtree Partners, to control their destiny. I believe that Oracle is looking for publicity by trying to make for itself a "name" as an "activist investor" in the medical field.
  • BIOLASE, under my management, has improved revenues from an annualized run rate of products and services revenue of approximately $20 million based on the nine months ended September 30, 2010, to approximately $56 million for the year ended December 31, 2013. During this period, we expanded our product line from one well outdated WaterLase system to 3 advanced WaterLase systems and several cutting edge diode laser systems alongside a full complement of other truly innovative dental technologies such as ConBeam digital Radiography and the top of the line 3Shape Trio CAD/CAM digital impressions. Further, the newly developed proprietary Galaxy BioMill open architecture chair-side milling system, along with distribution of Stratasys (SSYS) OrthoDesk 3D printing, will be launched for marketing in the current quarter. This is the widest product offerings in BIOLASE's history.
  • In this process of re-structuring and re-launching BIOLASE's entire business into the first Total Technology Solution provider for Dental Practices, BIOLASE incurred a non-GAAP net loss of $13.3 million for the period from October 1, 2010 through March 31, 2014. Considering legal expenses related to the director dispute and shareholder litigation brought by Oracle of $682,000 during the three months ended March 31, 2014, and a one-time charge of approximately $1 million to our reserve for excess and obsolete inventory during the third quarter ended September 30, 2013, which was primarily related to inventory purchases made by prior management, the adjusted non-GAAP net loss for the period from October 1, 2010 through March 31, 2014 is approximately $11.7 million. This 3 year period loss needs to be compared to a non-GAAP net loss of $10.6 million for the nine months only ended September 30, 2010 that BIOLASE experienced right before my becoming the CEO with new management.
  • Further, during the period from October 1, 2010 through March 31, 2014, we invested approximately $14.8 million in engineering and development. Had I halted this continued investment in our future, BIOLASE would have generated adjusted non-GAAP net income, excluding engineering and development, of approximately $3.1 million. The investment in R&D has contributed BIOLASE building the largest array of cutting edge high tech products in its history that we expect to be a strong contributor of imminent and significant future growth.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 25,500 laser systems. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE®, WaterLase®, and Total Technology Solution™ are registered trademarks or trademarks of BIOLASE, Inc.

Non-GAAP Disclosure
The non-GAAP financial information contained herein are a supplement to the corresponding financial measures prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the Company's on-going core operating performance.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provide a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.

Management uses non-GAAP net (loss) income (defined as net loss before interest, taxes, depreciation and amortization, and stock-based other equity instruments, and other non-cash compensation) in its evaluation of the Company's core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that this non-GAAP financial information reflects an additional way of viewing aspects of our business that, when viewed with our GAAP results, provide a more complete understanding of factors and trends affecting our business.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives, product introductions and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

(financial table follows)

                               BIOLASE, INC.
 Reconciliation of GAAP Net (Loss) Income to Non-GAAP Net (Loss) Income and
                   Adjusted Non-GAAP Net Loss (Unaudited)
                               (in thousands)

                   Three                                   Three
                   Months       Twelve Months Ended        Months
                   Ended           December 31,            Ended
                   March   ----------------------------   December
                 31, 2014    2013      2012      2011     31, 2013   Total
                 --------  --------  --------  --------  --------- --------
GAAP net (loss)
 income          $ (4,887) $(11,482) $ (3,056) $ (4,486) $     174 $(23,737)
   expense, net       230       600       239       305        144    1,518
  Income tax
   (benefit)           24      (164)      111        89          6       66
   expense            175       601       513       695        240    2,224
   other equity
   and other non-
   expense            371     1,965     1,873     2,051        310    6,570
                 --------  --------  --------  --------  --------- --------
Non-GAAP net
 (loss) income     (4,087)   (8,480)     (320)   (1,346)       874  (13,359)
  One time legal
   related to
   dispute and
   brought by
   Oracle             682         -         -         -          -      682
  One time charge
   to increase
   reserve for
   excess and
   inventory            -     1,000         -         -          -    1,000
                 --------  --------  --------  --------  --------- --------
Adjusted non-GAAP
 net (loss)
 income            (3,405)   (7,480)     (320)   (1,346)       874  (11,677)
  Engineering &
   development        973     4,029     4,684     4,311        800   14,797
                 --------  --------  --------  --------  --------- --------
Adjusted non-GAAP
 net (loss)
 income excluding
 engineering &
 development     $ (2,432) $ (3,451) $  4,364  $  2,965  $   1,674 $  3,120
                 ========  ========  ========  ========  ========= ========

For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
SYS-CON Events announced today that Daiya Industry will exhibit at the Japanese Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ruby Development Inc. builds new services in short period of time and provides a continuous support of those services based on Ruby on Rails. For more information, please visit https://github.com/RubyDevInc.
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
Infoblox delivers Actionable Network Intelligence to enterprise, government, and service provider customers around the world. They are the industry leader in DNS, DHCP, and IP address management, the category known as DDI. We empower thousands of organizations to control and secure their networks from the core-enabling them to increase efficiency and visibility, improve customer service, and meet compliance requirements.
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...